Source comparison
Tesamorelin Mechanism of Action: GHRH vs GH vs IGF-1 Comparison
Mechanism Binds GHRH receptors → stimulates endogenous GH release Exogenous GH replacement → direct receptor binding Direct IGF-1 receptor agonism → bypasses GH pathway Tesamorelin preserves pulsatile GH secretion; rhGH creates sustained supraphysiologic level
This comparison does not assign a generated winner or score.
- Mechanism
- Binds GHRH receptors → stimulates endogenous GH release
- Exogenous GH replacement → direct receptor binding
- Direct IGF-1 receptor agonism → bypasses GH pathway
- Tesamorelin preserves pulsatile GH secretion; rhGH creates sustained supraphysiologic levels
- Pulsatility
- Maintains natural 3–5 pulses/24hr cycle
- Continuous elevation. Non-pulsatile
- Continuous elevation. Bypasses GH entirely
- Pulsatile GH optimizes metabolic signaling, reduces insulin resistance risk
- VAT Reduction
- 12–18% at 26 weeks (clinical trials)
- 10–15% (variable, dose-dependent)
- Minimal direct lipolytic effect
- Tesamorelin shows consistent VAT selectivity across trials
- IGF-1 Elevation
- Physiologic increase (mean +88 ng/mL)
- Supraphysiologic increase (dose-dependent)
- Direct replacement. Bypasses hepatic regulation
- Tesamorelin elevates IGF-1 within normal range; rhGH often exceeds physiologic levels
- Half-Life
- 26–38 minutes (peptide); 3–4hr (GH effect)
- 2–3 hours (rhGH formulation-dependent)
- 12–16 hours
- Short half-life doesn't equal short effect. Pituitary secretion continues post-injection
- Regulatory Status
- FDA-approved for HIV-associated lipodystrophy
- FDA-approved for GH deficiency, wasting syndromes
- Off-label only (no FDA-approved formulation for lipolysis)
- Tesamorelin is the only FDA-approved GHRH analog for visceral adiposity reduction